| Date | Title | Description |
| 18.01.2024 | Eurocine Vaccines contracts Artemis Bioservices as CRO | Eurocine Vaccines contracts Artemis Bioservices as CRO
Thu, Jan 18, 2024 12:38 CET Report this content
Eurocine Vaccines AB (publ) ("Eurocine Vaccines" or "the Company") announces today that the Company has contracted Ar... |
| 28.11.2023 | Correction - Eurocine Vaccines discloses interim report for July – September 2023 | Correction - Eurocine Vaccines discloses interim report for July – September 2023
Tue, Nov 28, 2023 10:41 CET Report this content
Correction to previous press release since the interim report was not attached earlier.
Eurocine Vaccines AB (... |
| 28.11.2023 | Eurocine Vaccines discloses interim report for Juli – September 2023 | Eurocine Vaccines discloses interim report for Juli – September 2023
Tue, Nov 28, 2023 09:04 CET Report this content
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the interim report for July to September 2023. Below is a... |
| 28.11.2023 | Correction - Eurocine Vaccines discloses interim report for July – September 2023 | Correction - Eurocine Vaccines discloses interim report for July – September 2023
Tue, Nov 28, 2023 10:41 CET Report this content
Correction to previous press release since the interim report was not attached earlier.
Eurocine Vaccines AB (... |
| 28.11.2023 | Eurocine Vaccines discloses interim report for Juli – September 2023 | Eurocine Vaccines discloses interim report for Juli – September 2023
Tue, Nov 28, 2023 09:04 CET Report this content
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the interim report for July to September 2023. Below is a... |
| 30.08.2023 | Eurocine Vaccines discloses year-end report for the fiscal year 2022/2023 | Eurocine Vaccines discloses year-end report for the fiscal year 2022/2023
Wed, Aug 30, 2023 08:21 CET Report this content
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2022/2023. B... |
| 24.05.2023 | Eurocine Vaccines discloses interim report for July 2022 – March 2023 | Eurocine Vaccines discloses interim report for July 2022 – March 2023
Wed, May 24, 2023 08:00 CET Report this content
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the interim report for July 2022 to Ma... |
| 24.05.2023 | Eurocine Vaccines discloses interim report for July 2022 – March 2023 | Eurocine Vaccines discloses interim report for July 2022 – March 2023
Wed, May 24, 2023 08:00 CET Report this content
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the interim report for July 2022 to Ma... |
| 04.05.2023 | Eurocine Vaccines receives grant from Merck Group | Eurocine Vaccines receives grant from Merck Group
Thu, May 04, 2023 08:00 CET Report this content
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) announces today that the Company has received a grant of SEK 300,000 from M... |
| 28.02.2023 | Eurocine Vaccines discloses half-year report for July – December 2022 | Eurocine Vaccines discloses half-year report for July – December 2022
Tue, Feb 28, 2023 08:15 CET Report this content
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the half-year report for July to Decem... |
| 20.02.2023 | Eurocine Vaccines’ Director of Preclinical Development invited to lecture at UCL School of Pharmacy | Eurocine Vaccines’ Director of Preclinical Development invited to lecture at UCL School of Pharmacy
Mon, Feb 20, 2023 15:01 CET Report this content
Eurocine Vaccines (“Eurocine” or the “Company”) announces today that the Company’s Director ... |
| 17.01.2023 | Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia | Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia
Tue, Jan 17, 2023 21:26 CET Report this content
In the pursuit of the most advanced vaccines of high potential, the board of Eurocine Vaccines has decided t... |
| 20.12.2022 | Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate | Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
Tue, Dec 20, 2022 12:03 CET Report this content
As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology pl... |
| 30.08.2022 | Eurocine Vaccines´ newly added HSV-2 vaccine candidate gains patent protection in South Korea | Eurocine Vaccines´ newly added HSV-2 vaccine candidate gains patent protection in South Korea
Tue, Aug 30, 2022 10:06 CET Report this content
Eurocine Vaccines has received a Notice of Decision to Grant from the Korean Intellectual Property... |
| 25.08.2022 | Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022 | Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022
Thu, Aug 25, 2022 08:00 CET Report this content
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby discloses the year-end report for the fiscal year 2021/2022. B... |
| 28.07.2022 | Disclosure notice in Eurocine Vaccines | Disclosure notice in Eurocine Vaccines
Thu, Jul 28, 2022 12:50 CET Report this content
Eurocine Vaccines AB hereby announces that Flerie Invest AB has acquired shares in the company and now holds more than 15 % of the shares.
Flerie Invest ... |
| 04.07.2022 | Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate | Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate
Mon, Jul 04, 2022 09:00 CET Report this content
Expanding its portfolio, Eurocine Vaccines adds considerable value by the new HS... |
| 14.06.2022 | Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate | Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Tue, Jun 14, 2022 16:26 CET Report this content
Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a res... |
| 20.05.2022 | Eurocine Vaccines publishes interim report for July 2021 – March 2022 | Eurocine Vaccines publishes interim report for July 2021 – March 2022
Fri, May 20, 2022 08:15 CET Report this content
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby publishes the interim report for July 2021 to December 2022. Below... |
| 08.03.2022 | Eurocine Vaccines publishes CEO interview | Eurocine Vaccines publishes CEO interview
Tue, Mar 08, 2022 07:46 CET Report this content
CEO Hans Arwidsson discussed the vaccine portfolio, the progress with the chlamydia vaccine candidate, and the future plans for the business in an int... |
| 16.02.2022 | Eurocine Vaccines publishes half-year report for July - December 2021 | Eurocine Vaccines publishes half-year report for July - December 2021
Wed, Feb 16, 2022 08:00 CET Report this content
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the half-year report for July to December 2021. Below is a sum... |
| 15.02.2022 | Eurocine Vaccines enters into agreement with Flerie Invest to secure exercise of warrants of series TO 4 | Eurocine Vaccines enters into agreement with Flerie Invest to secure exercise of warrants of series TO 4
Tue, Feb 15, 2022 18:44 CET Report this content
Eurocine Vaccines AB (“Eurocine Vaccines” or “the Company”) announces today that the Co... |
| 21.12.2021 | Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application | Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application Tue, Dec 21, 2021 19:01 CET
The Board of Directors of Eurocine Vaccines has resolved to request scientific advice f... |
| 01.12.2021 | Eurocine Vaccines´ Chlamydia vaccine candidate elicits both antibody and T cell responses | Eurocine Vaccines´ Chlamydia vaccine candidate elicits both antibody and T cell responses Wed, Dec 01, 2021 07:30 CET
In the latest preclinical study, it was shown that intramuscular immunization with the Chlamydia vaccine candidate elicits... |
| 17.11.2021 | Eurocine Vaccines discloses interim report for July – September 2021 | Eurocine Vaccines discloses interim report for July – September 2021 Wed, Nov 17, 2021 09:59 CET
Eurocine Vaccines AB hereby discloses the interim report for July – September 2021. Below is a summary of the report. The full report is availa... |
| 17.11.2021 | Correction: Eurocine Vaccines discloses interim report for July – September 2021 | Correction: Eurocine Vaccines discloses interim report for July – September 2021 Wed, Nov 17, 2021 13:15 CET
Correction: In the interim report for July – September 2021, information whether the report has been reviewed by the company’s audi... |
| 17.11.2021 | Eurocine Vaccines discloses interim report for July - September 2021 | Eurocine Vaccines AB hereby discloses the interim report for July - September 2021. Below is a summary of the report. The full report is available at Eurocine Vaccines' website (https://www.eurocine-vaccines.com/) and as an attachment.
2021... |
| 15.10.2021 | Disclosure notice in Eurocine Vaccines | Disclosure notice in Eurocine Vaccines Fri, Oct 15, 2021 19:23 CET
Eurocine Vaccines hereby announces that Flerie Invest AB has acquired shares in the company and holds above 10 % of the shares in the company. Flerie Invest AB holds approxi... |
| 31.08.2021 | Eurocine Vaccines discloses year-end report for the fiscal year 2020/2021 | Eurocine Vaccines discloses year-end report for the fiscal year 2020/2021 Tue, Aug 31, 2021 08:15 CET
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby discloses the year-end report for the fiscal year 2020/2021. Below is a summary of the r... |
| 25.08.2021 | Eurocine Vaccines : extends its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia Biotechnology | Eurocine Vaccines AB has decided to evaluate a diagnostic test of chlamydia antibodies in blood as an extension of its portfolio and has widened the license agreement with Spixia Biotechnology AB to also include diagnostic tests of chlamydi... |
| 25.08.2021 | Eurocine Vaccines extends its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia Biotechnology | Eurocine Vaccines extends its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia Biotechnology Wed, Aug 25, 2021 08:58 CET
Eurocine Vaccines AB has decided to evaluate a diagnostic test of chlamydi... |
| 10.06.2021 | Eurocine Vaccines prepares to evaluate two more vaccine candidates | Eurocine Vaccines prepares to evaluate two more vaccine candidates Thu, Jun 10, 2021 10:45 CET
As part of its portfolio strategy, Eurocine Vaccines is actively searching for new vaccine candidates to expand the portfolio. Of the currently o... |
| 27.05.2021 | Eurocine Vaccines publishes interim report for July 2020 - March 2021 | Eurocine Vaccines publishes interim report for July 2020 - March 2021 Thu, May 27, 2021 08:00 CET
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the interim report for July 2020 to March 2021. Below is a summary of the report. ... |
| 19.05.2021 | Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19 | Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19 Wed, May 19, 2021 16:30 CET
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine™ together wi... |
